ENTA

6.28

7.17% 0.42

Handel nachbörslich: 6.28

Enanta Pharmaceuticals Inc (ENTA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$5.86

Offen:

$5.84

24-Stunden-Volumen:

635.58K

Relative Volume:

2.46

Marktkapitalisierung:

$133.10M

Einnahmen:

$73.62M

Nettoeinkommen (Verlust:

$-138.24M

KGV:

-0.9949

EPS:

-6.3125

Netto-Cashflow:

$-99.19M

1W Leistung:

+4.15%

1M Leistung:

-30.84%

6M Leistung:

-45.06%

1J Leistung:

-26.29%

1-Tages-Spanne:

$5.72

$6.31

1-Wochen-Bereich:

$5.70

$6.56

52-Wochen-Spanne:

$5.70

$17.80

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Firmenname

Enanta Pharmaceuticals Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

617 607 0800

Adresse

500 ARSENAL STREET, WATERTOWN, MA

Mitarbeiter

131

Twitter

@EnantaPharma

Nächster Verdiensttermin

2024-11-25

Neueste SEC-Einreichungen

ENTA's Discussions on Twitter

Vergleichen Sie ENTA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ENTA Enanta Pharmaceuticals Inc	6.28	133.10M	73.62M	-138.24M	-99.19M	-6.56
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-08-09	Herabstufung	JP Morgan	Neutral → Underweight
2023-08-08	Herabstufung	Jefferies	Buy → Hold
2022-12-09	Eingeleitet	H.C. Wainwright	Buy
2022-07-06	Hochstufung	Evercore ISI	In-line → Outperform
2022-06-01	Hochstufung	Evercore ISI	Underperform → In-line
2021-10-07	Eingeleitet	Jefferies	Buy
2021-09-09	Eingeleitet	SVB Leerink	Mkt Perform
2021-01-29	Hochstufung	JP Morgan	Underweight → Neutral
2020-11-24	Eingeleitet	Evercore ISI	Underperform
2020-08-28	Fortgesetzt	ROTH Capital	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-27	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2020-03-17	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-11-22	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-26	Herabstufung	JP Morgan	Neutral → Underweight
2019-05-24	Eingeleitet	Wolfe Research	Outperform
2019-04-23	Hochstufung	Berenberg	Hold → Buy
2018-12-13	Eingeleitet	Berenberg	Hold
2018-06-06	Eingeleitet	ROTH Capital	Buy
2018-02-08	Herabstufung	JP Morgan	Overweight → Neutral
2018-01-02	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2017-11-21	Bestätigt	RBC Capital Mkts	Outperform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-07-11	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2016-04-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Bestätigt	Barclays	Underweight
2015-10-23	Herabstufung	Barclays	Equal Weight → Underweight
2015-10-23	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform

Alle ansehen

Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten

Dec 19, 2024

Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 19, 2024

Dec 17, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024

Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024

Dec 15, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com

Dec 15, 2024

Dec 14, 2024

(ENTA) Technical Data - Stock Traders Daily

Dec 14, 2024

Dec 13, 2024

Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada

Dec 13, 2024

FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World

Dec 13, 2024

Dec 12, 2024

Leerink Partnrs Has Positive Outlook of ENTA FY2025 Earnings - MarketBeat

Dec 12, 2024

Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 By Investing.com - Investing.com Canada

Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock By Investing.com - Investing.com Canada

Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 - Investing.com

Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock - Investing.com

Dec 11, 2024

Point72 Asset Management L.P. Buys New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 11, 2024

Dec 10, 2024

Enanta Pharmaceuticals chief scientific officer sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock By Investing.com - Investing.com Canada

Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock - Investing.com

Dec 10, 2024

Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

Enanta logs phase II RSV win with zelicapavir - BioWorld Online

Dec 09, 2024

Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials - MarketWatch

Dec 09, 2024

LogoEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire

Dec 09, 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - BioSpace

Dec 09, 2024

Enanta's RSV Drug Zelicapavir Shows Strong Antiviral Effects in Landmark Pediatric Trial - StockTitan

Dec 09, 2024

Dec 06, 2024

Enanta Pharma to Unveil Breakthrough RSV Pediatric Trial ResultsKey Phase 2 Data Coming - StockTitan

Dec 06, 2024

Dec 05, 2024

Enanta stock touches 52-week low at $7.99 amid market challenges - Investing.com Nigeria

Dec 05, 2024

Dec 04, 2024

Erste Asset Management GmbH Purchases New Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 04, 2024

Dec 01, 2024

Enanta Pharmaceuticals (FRA:9EP) 3-Year FCF Growth Rate : -9.20% (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Caligan Partners LP Cuts Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 01, 2024

Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.50 - MarketBeat

Dec 01, 2024

Nov 30, 2024

Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com

Nov 30, 2024

Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World

Nov 30, 2024

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St

Nov 30, 2024

Nov 29, 2024

Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance

Nov 29, 2024

Nov 28, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com

Nov 28, 2024

ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Robert W. Baird Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World

Nov 28, 2024

Nov 27, 2024